Pharma

daiichi-sankyo-s-comments-enrages-the-singh-family-the-former-shareholder-and-owners-of-ranbaxy

Daiichi's comments upset former Ranbaxy owners

  • Japan
  • |
  • News

Singapore: Japanese drugmaker Daiichi Sankyo, which currently holds a majority stake in Ranbaxy, had earlier highlighted that it believes that former shareholders of Ranbaxy concealed and misrepresented critical information concerning the... Read more

us-fda-panel-s-opinion-was-somewhat-at-odds-with-the-agency-s-own-scientists-who-issued-a-negative-review-of-the-merck-drug

FDA votes +ve for Merck drug despite glitches in trial...


  • US
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: An US FDA panel has voted that Merck & Co experimental insomnia drug appears to be safe and effective, despite... Read more

johnson-johnson-launched-11-new-products-since-2009-which-have-raked-in-17-percent-of-its-total-pharma-sales-last-year

J&J to seek nod for 11 new drugs by 2017


  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Johnson & Johnson (J&J) revealed that it is aiming to apply for approval of 10 new drugs in the US and Europe,... Read more

one-third-of-ranbaxy-s-14-600-global-sales-staff-may-lose-their-jobs

Ranbaxy may fire 1/3rd of its global sales staff

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Ranbaxy Laboratories is contemplating on slashing its global sales staff by about a third, with a majority of the job cuts expected... Read more

daiichi-may-take-legal-action-against-former-shareholders-of-ranbaxy-as-it-believes-that-they-concealed-and-misrepresented-critical-information-concerning-the-us-department-of-justice-doj-and-us-fda-inves

Daiichi may take legal action against ex-Ranbaxy promoters

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Breaking its silence for the first time in 10 days after Indian drug major Ranbaxy's $500 million settlement of the US Food and... Read more

ranbaxy-reflects-on-the-its-actions-that-it-been-taking-in-recent-years-to-ensure-the-safety-and-efficacy-of-all-its-products

Ranbaxy reflects on steps taken for product safety

  • India
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Ranbaxy Laboratories highlighted some of the major specific actions the company has been taking in recent years to address certain... Read more

axway-will-help-sanofi-ensure-that-all-divisions-subsidiaries-and-new-acquisitions-are-able-to-efficiently-and-securely-exchange-and-manage-data-in-a-way-that-is-uniform-globally

Axway helps Sanofi to ‘fool-proof’ its IT infrastructure

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Sanofi joined hands with Axway in order to streamline processes and transform its technology infrastructure into an efficient... Read more

winners-of-glaxosmithkline-gsk-discovery-fast-track-competition-will-partner-with-investigators-on-gsk-s-discovery-partnerships-with-academia-dpac-team

GSK launches discovery competition for researchers

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: GlaxoSmithKline (GSK) launched Discovery Fast Track, a competition designed to accelerate the translation of academic research... Read more

pfizer-stops-its-phase-iii-study-of-inotuzumab-ozogamicin

Pfizer halts 'useless' phase III lymphoma study

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Pfizer has discontinued its phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of... Read more

alchemia-provides-update-on-fondaparinux-its-new-collaboration-with-merck-serono-and-its-current-ha-irinotecan-phase-iii-clinical-trial

Alchemia provides update on its core projects

  • Australia
  • |
  • Company Results
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Australia-based Alchemia has provided commercial update on four of its key projects, including its marketed drug fondaparinux;... Read more

globaldata-report-japan-s-branded-hronic-myeloid-leukemia-cml-therapeutics-market-will-grow-to-usd565-million-in-2022-at-a-cagr-of-1

Japan leukemia market to grow to $565mn in 2022

  • Japan
  • |
  • Analysis
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: A new study by research and consulting firm GlobalData, highlighted that Japan's chronic myeloid leukemia (CML) market is going... Read more

astrazeneca-s-new-usd500-million-headquarters-will-be-located-at-the-south-of-cambridge

AstraZeneca to move HQ to $500 mn home in Cambridge

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: AstraZeneca is looking to move its research and global headquarters to Cambridge, UK, and has zeroed in on a site located at... Read more

Previous 1 3 4 5 6 7

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X